Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme (Q33518926)

27 July 2017

1 reference

5 November 2020

Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme (English)

1 reference

27 July 2017

1 reference

5 November 2020

1 reference

5 November 2020

angiogenesis inhibitor

1 reference

5 November 2020

Joost J C Verhoeff

1

1 reference

27 July 2017

Olaf van Tellingen

2

1 reference

27 July 2017

An Claes

3

1 reference

27 July 2017

Lukas J A Stalpers

4

1 reference

27 July 2017

Myra E van Linde

5

1 reference

27 July 2017

Dirk J Richel

6

1 reference

27 July 2017

William P J Leenders

7

1 reference

27 July 2017

Wouter R van Furth

8

1 reference

27 July 2017

language of work or name

English

0 references

publication date

16 December 2009

5 references

27 July 2017

14 March 2019

3 April 2019

25 April 2019

5 November 2020

5 references

27 July 2017

14 March 2019

3 April 2019

25 April 2019

5 November 2020

9

1 reference

27 July 2017

444

1 reference

Creative Commons Attribution 2.0 Generic

27 July 2017

4 references

14 March 2019

3 April 2019

25 April 2019

on focus list of Wikimedia project

5 November 2020

copyright status

copyrighted

0 references

ScienceSource

0 references

exact match

https://scigraph.springernature.com/pub.10.1186/1471-2407-9-444

0 references

cites work

VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Bevacizumab and carboplatin increase survival and asymptomatic tumor volume in a glioma model

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Response criteria for glioma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Modes of resistance to anti-angiogenic therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Contrast enhanced MRI and intravital fluorescence microscopy indicate improved tumor microcirculation in highly vascularized melanomas upon short-term anti-VEGFR treatment

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Chemoradiotherapy in malignant glioma: standard of care and future directions

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Angiogenesis in brain tumours

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Chemotherapy delivery issues in central nervous system malignancy: a reality check.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Internet-enabled high-resolution brain mapping and virtual microscopy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Magnetic resonance as a cancer imaging biomarker

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Tumours can adapt to anti-angiogenic therapy depending on the stromal context: lessons from endothelial cell biology

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Imaging angiogenesis: applications and potential for drug development

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Invasion as limitation to anti-angiogenic glioma therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Use of dexamethasone in treatment of cerebral edema associated with brain tumors.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Molecular regulation of vessel maturation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Glioma invasion in the central nervous system

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

High-dose conformal radiotherapy for supratentorial malignant glioma: a historical comparison.

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-444

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-444

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-444

Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-444

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-444

MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-444

Effect of bevacizumab on radiation necrosis of the brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-444

Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-444

Selection bias, phase II trials, and the FDA accelerated approval process

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-444

Response criteria for phase II studies of supratentorial malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-444

Magnetic resonance imaging-based detection of glial brain tumors in mice after antiangiogenic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-444

Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-444

Regression of brain metastases of renal cell carcinoma with antiangiogenic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-444

MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-444

The added value of the apparent diffusion coefficient calculation to magnetic resonance imaging in the differentiation and grading of malignant brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-444

Predicting patterns of glioma recurrence using diffusion tensor imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-444

Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-444

Metabolic imaging of cerebral gliomas: spatial correlation of changes in O-(2-18F-fluoroethyl)-L-tyrosine PET and proton magnetic resonance spectroscopic imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-444

Thallium-201 single-photon emission computed tomography as an early predictor of outcome in recurrent glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-444

Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-444

Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-444

Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-444

An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Brain metastasis in renal cell cancer responding to sunitinib.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801683

Neoplastic angiogenesis--not all blood vessels are created equal

31 October 2018

1 reference

12 December 2020

The effect of bevacizumab (Avastin) on neuroimaging of brain metastases

1 reference

12 December 2020

Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network

1 reference

12 December 2020

Bevacizumab in the treatment of a patient with metastatic colorectal carcinoma with brain metastases

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2407-9-444

1 reference

Dimensions Publication ID

27 July 2017

0 references

1 reference

27 July 2017

1 reference